Compare AX & BLLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AX | BLLN |
|---|---|---|
| Founded | 1999 | 2016 |
| Country | United States | United States |
| Employees | N/A | 713 |
| Industry | Savings Institutions | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 5.2B |
| IPO Year | 2004 | N/A |
| Metric | AX | BLLN |
|---|---|---|
| Price | $97.45 | $126.86 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 7 |
| Target Price | $103.14 | ★ $126.71 |
| AVG Volume (30 Days) | 406.7K | ★ 711.6K |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 6.33 | N/A |
| Revenue | ★ $65,789,000.00 | N/A |
| Revenue This Year | $24.76 | $46.29 |
| Revenue Next Year | $10.86 | $30.14 |
| P/E Ratio | $15.33 | ★ N/A |
| Revenue Growth | ★ 1.78 | N/A |
| 52 Week Low | $74.89 | $61.96 |
| 52 Week High | $101.92 | $138.70 |
| Indicator | AX | BLLN |
|---|---|---|
| Relative Strength Index (RSI) | 60.75 | 65.63 |
| Support Level | $91.90 | $79.07 |
| Resistance Level | $100.31 | $138.70 |
| Average True Range (ATR) | 2.62 | 6.68 |
| MACD | 0.14 | 0.68 |
| Stochastic Oscillator | 73.15 | 90.04 |
Axos Financial Inc is a bank holding company that operates through its bank subsidiary, BofI Federal Bank, a nationwide bank that provides financing for single and multifamily residential properties, small to medium-size businesses in certain sectors, and selected specialty finance receivables. Its operating segments are banking business segment and securities business segment. The bank distributed its products through a wide range of retail distribution channels, including only banking brands, affinity groups, and sales teams, among others. The majority of the bank's mortgage exposure is titled toward the state of California, particularly its southern region. Net interest income is a majority of the bank's revenue.
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.